Alexion Reaches New 52-Week High (ALXN)

NEW YORK ( TheStreet) -- Alexion Pharmaceuticals (Nasdaq: ALXN) hit a new 52-week high Monday as it is currently trading at $87.98, above its previous 52-week high of $87.63 with 1.5 million shares traded as of 2:55 p.m. ET. Average volume has been 1.2 million shares over the past 30 days.

Alexion has a market cap of $13.68 billion and is part of the health care sector and drugs industry. Shares are up 18.5% year to date as of the close of trading on Friday.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologic therapeutic products in the United States, Europe, Latin America, Japan, and the Asia Pacific. The company has a P/E ratio of 93.3, above the average drugs industry P/E ratio of 92.5 and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Alexion as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. You can view the full Alexion Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.
null

If you liked this article you might like

Alexion Could Target Sage, Ra Pharma: Analyst

Dow, S&P 500 and Nasdaq at New Records as Promise of Tax Reform Boosts Banks

Stocks Back at Highs as Apple Gains on iPhone 8, iPhone X Release

Tech in Wait-and-See Mode Ahead of Apple Event, Financials Rise on Tax Talk

Stocks Come Off Highs as Apple Wait Counters Boost From Tax Reform Talk